Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab maintenance after first-line platinum chemotherapy in metastatic squamous NSCLC
2015-001123-22Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Aug 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Aug 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-001123-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001123-22.